NCT04057261

Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: RWTH Aachen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In an unbiased metabolomics approach with subsequent pathway analyses, the current study seeks to examine the effect of Liraglutide treatment on the metabolic signature in treated patients as well as the effect of Liraglutide on various echocardiographic parameters of cardiac function and rhythm profile, thus paving the way for future research to explain the effects of Liraglutide on cardiovascular mortality and overall mortality in treated patients.

Conditions

• Type 2 Diabetes
• Cardiovascular Diseases

Interventions

Type	Name	Description
DRUG	Liraglutide Pen Injector [Victoza]	Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
DRUG	Placebo	Matching Placebo once daily, subcutaneous injection via pre-filled pen.

Timeline

• Start date: 2020-11-01
• Primary completion: 2022-08-01
• Completion: 2022-11-01
• First posted: 2019-08-15
• Last updated: 2021-03-10

Locations

1 site across 1 country: Germany